FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Significant CGMP Violations in Prime Lab LLC

FDA warns Ponce, Puerto Rico-based Prime Labs about significant CGMP regulation violations in its production of finished drugs.

latest-news-card-1
Human Drugs

Leiters Health Recalls Superpotent IV Bags

Leiters Health recalls 33 lots of vancomycin IV bags, phenylephrine IV bags, and fentanyl IV bags due to the potential for superpotency.

latest-news-card-1
Federal Register

Vertex Gets Priority Voucher

Federal Register notice: FDA issues a priority review voucher (pediatric disease product) to Vertex Pharmaceuticals for gaining approval of Casgevy (e...

latest-news-card-1
Medical Devices

Bausch + Lomb Excimer Laser Approved

FDA approves Bausch + Lombs Teneo Excimer Laser Platform for LASIK vision correction surgery for myopia and myopic astigmatism.

latest-news-card-1
Medical Devices

FDA OKs Medtronics Brain Stimulator

FDA approves a Medtronic PMA for its Percept RC Deep Brain Stimulation system.

latest-news-card-1
Human Drugs

First-Cycle Drug Approvals Improve: Report

CDER first-cycle drug approvals last year shot up to 84% (46 of 55 NDAs) from 76% (28 of 37 NDAs) in 2022, according to a just-released approvals repo...

Medical Devices

FDA Endorses Vaporized Hydrogen Peroxide

FDA endorses vaporized hydrogen peroxide to be an established sterilization method for medical devices.

latest-news-card-1
Federal Register

Info Collection on Drug Expedited Programs

Federal Register notice: FDA seeks comments on an information collection extension entitled Expedited Programs for Serious Conditions Drugs and Biolo...

latest-news-card-1
Medical Devices

Megadyne Recalls Patient Return Electrodes

Megadyne Medical Product recalls its Mega Soft Universal Patient Return Electrodes to update its Instructions for Use and product labeling.

latest-news-card-1
Human Drugs

Cabaletta Bio Gains Fast Track on CABA-201

FDA grants Cabaletta Bio a fast track designation for CABA-201, an investigational 4-1BB-containing CD19-CAR T cell therapy.